[Current Data] Rule running report - 2024-05-29 21:48:06.246884

Nr2MedPage Today) -- Patients with high-risk gastrointestinal stromal tumors (GISTs) had a 60% improvement in 3-year disease-free survival (DFS) with 6 versus 3 years of maintenance imatinib, a randomized trial… succesfully run! 0 Anläufe!